The US Food and Drug Administration is questioning whether ocular toxicity with GlaxoSmithKline plc’s belantamab mafodotin outweighs the drug’s benefits in relapsed/refractory multiple myeloma.
The ocular events seen in the belantamab clinical program are a “major safety concern” and one not typically seen with...





